Results 21 to 30 of about 51,273 (262)

Prophylactic central lymph node dissection in differentiated thyroid cancer – benefits and risk [PDF]

Folia Medica, 2022
Introduction: Papillary thyroid cancer is the most common thyroid malignancy. Lymph nodes involvement is common in differentiated thyroid cancer, and cervical lymph node micrometastases are observed in up to 85% of patients with papillary thyroid cancer ...
Gancho G. Kostov, Rossen S. Dimov, Mladen I. Doykov   +2 more
doaj   +3 more sources

Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer

Endocrine Regulations, 2017
Objectives. NLR (neutrophil-lymphocyte ratio) and PLR (platelet-lymphocyte ratio) are prognostic markers of differentiated thyroid cancers. In our study, we evaluated NLR, PLR and C-reactive protein (CRP) for predicting the occurence of differentiated ...
Ozmen S, Timur O, Calik I, Altinkaynak K, Simsek E, Gozcu H, Arslan A, Carlioglu A   +7 more
doaj   +1 more source

Well-differentiated thyroid cancer disclosed during pregnancy. Management experience

Эндокринная хирургия, 2015
Thyroid cancer have the second place as malignancy detectable during pregnancy. Disclose of thyroid cancer during pregnancy raises many questions among endocrinologists, oncologists and obstetricians.
A. A. Ilyin, P. O. Rumyantsev, D. N. Derbugov, D. N. Semin, N. V. Severskaya, P. A. Isaev, S. V. Vasilkov, V. S. Medvedev, V. V. Polkin   +8 more
doaj   +1 more source

Significance of telomerase reverse-transcriptase promoter mutations in differentiated thyroid cancer

Formosan Journal of Surgery, 2021
Background: Telomerase reverse-transcriptase (TERT) encodes the reverse transcriptase of telomerase, and TERT promoter mutations are enriched in advanced thyroid cancer.
Hung-Fei Lai, Chi-Yu Kuo, Shih-Ping Cheng   +2 more
doaj   +1 more source

A novel risk stratification model based on tumor size and multifocality to predict recurrence in pediatric PTC: comparison with adult PTC

Frontiers in Endocrinology
BackgroundPediatric papillary thyroid cancer presents with a more advanced stage of disease than adult PTC; and it is more likely to be aggresive and distant metastases, although the survival rate is high.MethodsA retrospective observational study was ...
Rui Du, Ying Zhang, Jiedong Kou, Jingting Li, Chengqiu Sui, Daqi Zhang, Yantao Fu, Le Zhou, Qingfeng Fu, Fang Li, Gianlorenzo Dionigi, Gianlorenzo Dionigi, Nan Liang, Hui Sun   +13 more
doaj   +1 more source

The genomic and evolutionary landscapes of anaplastic thyroid carcinoma

Cell Reports
Summary: Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown.
Peter Y.F. Zeng, Stephenie D. Prokopec, Stephen Y. Lai, Nicole Pinto, Michelle A. Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D. Williams, Christopher J. Howlett, Paul Plantinga, Matthew J. Cecchini, Alfred K. Lam, Iram Siddiqui, Jianxin Wang, Ren X. Sun, John D. Watson, Reju Korah, Tobias Carling, Nishant Agrawal, Nicole Cipriani, Douglas Ball, Barry Nelkin, Lisa M. Rooper, Justin A. Bishop, Cathie Garnis, Ken Berean, Norman G. Nicolson, Paul Weinberger, Ying C. Henderson, Christopher M. Lalansingh, Mao Tian, Takafumi N. Yamaguchi, Julie Livingstone, Adriana Salcedo, Krupal Patel, Frederick Vizeacoumar, Alessandro Datti, Liu Xi, Yuri E. Nikiforov, Robert Smallridge, John A. Copland, Laura A. Marlow, Martin D. Hyrcza, Leigh Delbridge, Stan Sidhu, Mark Sywak, Bruce Robinson, Kevin Fung, Farhad Ghasemi, Keith Kwan, S. Danielle MacNeil, Adrian Mendez, David A. Palma, Mohammed I. Khan, Mushfiq Shaikh, Kara M. Ruicci, Bret Wehrli, Eric Winquist, John Yoo, Joe S. Mymryk, James W. Rocco, David Wheeler, Steve Scherer, Thomas J. Giordano, John W. Barrett, William C. Faquin, Anthony J. Gill, Gary Clayman, Paul C. Boutros, Anthony C. Nichols   +68 more
doaj   +1 more source

Mouse models of follicular and papillary thyroid cancer progression

Frontiers in Endocrinology, 2012
A significant number of well-differentiated thyroid cancers progress or recur, becoming resistant to current therapeutic options. Mouse models recapitulating the genetic and histological features of advanced thyroid cancer have been an invaluable tool ...
Marika A. Russo, Valeria G. Antico Arciuch, Antonio eDi Cristofano   +2 more
doaj   +1 more source

Transferrin receptor 1‐mediated iron uptake supports thermogenic activation in human cervical‐derived adipocytes

FEBS Letters, EarlyView.
In this study, we found that human cervical‐derived adipocytes maintain intracellular iron level by regulating the expression of iron transport‐related proteins during adrenergic stimulation. Melanotransferrin is predicted to interact with transferrin receptor 1 based on in silico analysis.
Rahaf Alrifai, Mizuki Seo, Gyath Karadsheh, Fachrur Rizal Mahendra, Máté Á Demény, Ferenc Győry, János András Mótyán, László Fésüs, Endre Kristóf, Rini Arianti   +9 more
wiley   +1 more source

Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors

Cancer Control, 2021
Background: Health-related quality of life (HRQoL) is important for differentiated thyroid cancer survivors, but data for Asian survivors is lacking.
Wing-Lok Chan MBBS, MSc, Horace Cheuk-Wai Choi PhD, Brian Lang MBBS, MS, Kai-Pun Wong MBBS, MS, Kwok-Keung Yuen MBChB, MSc, Ka-On Lam MBBS, Victor Ho-Fun Lee MBBS, MD, Dora Kwong MBBS, MD   +7 more
doaj   +1 more source

Managing differentiated thyroid cancer

BMJ, 2002
Although differentiated thyroid cancers are not common, they are as common as cervical cancer and multiple myeloma and are the commonest malignant endocrine tumours. Furthermore, they are among the few curable cancers. When managed according to best practice the vast majority of patients can expect cure, so good management is mandatory.
openaire   +3 more sources